Tuesday November 5, 11:39 AM
Cannabis could be legal in the UK as early as next year after clinical trials by GW Pharmaceuticals showed that it is an effective treatment for multiple sclerosis, the nerve wasting disease.
However, the drug will be in the form of a purified extract, available on prescription and only for a handful of diseases that cause nerve damage.
GW, the sole UK company with a licence to develop cannibis-based medicine, said four randomised trials found the drug statistically cut neuropathic pain, spasticity and sleep disturbance in MS patients and other people suffering from nerve damage.
As a result the company plans to apply to regulators for approval to market the treatment.
GW shares, which hit an 8-month high on Monday on speculation about
the MS trial, were down 5 per cent or 8p at 143p in early morning trade.
Copyright © FT Investor